

# State Corporation Commission

## 2020 Fiscal Impact Statement

**1. Bill Number:** HB66

**House of Origin**    ☐ Introduced    ☒ Substitute    ☐ Engrossed  
**Second House**    ☒ In Committee    ☐ Substitute    ☐ Enrolled

**2. Patron:** Carter

**3. Committee:** Commerce and Labor

**4. Title:** Health insurance; cost-sharing payments for prescription insulin drugs.

**5. Summary:** Prohibits health insurance companies and other carriers from setting an amount exceeding \$30 per 30-day supply that a covered person is required to pay at the point of sale in order to receive a covered prescription insulin drug. The measure also prohibits a provider contract between a carrier or its pharmacy benefits manager and a pharmacy from containing a provision (i) authorizing the carrier's pharmacy benefits manager or the pharmacy to charge, (ii) requiring the pharmacy to collect, or (iii) requiring a covered person to make a cost-sharing payment for a covered prescription insulin drug in an amount that exceeds such limitation.

**6. Budget Amendment Necessary:** No

**7. Fiscal Impact Estimates:** No fiscal impact on the State Corporation Commission

**8. Fiscal Implications:** None on the State Corporation Commission

**9. Specific Agency or Political Subdivisions Affected:** State Corporation Commission  
Bureau of Insurance

**10. Technical Amendment Necessary:**

**11. Other Comments:** House Bill 1403 was incorporated into House Bill 66.

**Date:** 2/4/20/V.Tompkins